Veraxa Biotech AG (VRXA) Price Prediction & ForecastVRXAVeraxa Biotech AG

Veraxa Biotech AG is not a good buy right now due to its extremely low current price of 1.35, a very low RSI of 13.838 indicating oversold conditions, and a staggering year-to-date change of -92.11%. The company is facing significant financial distress with a current ratio of 0.00 and negative total equity of -14,448,149, which raises serious concerns about its solvency and operational viability. The main risk is the company's inability to generate positive cash flow, as indicated by a forward P/E of 0 and a price-to-book ratio of -12.915473, which suggests that the market has little confidence in its future profitability. Overall, the combination of poor financial health and a declining stock price makes this a risky investment at this time.

Veraxa Biotech AG (VRXA) last closed at $1.35, losing -6.25%. These facts feed the 1-day and 1-week VRXA price prediction above.